Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster and catch-up study of Novartis MenB recombinant + OMV NZ vaccine in toddlers previously primed as infants
2009-011676-30Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, meningococcal meningitis and meningococcemia (6 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoint. Started Apr 2009; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2009-011676-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011676-30.